1. Nexus Newsfeed: Cannabidiol may soon be used in the emergency room
By Lance Johnson
During a cardiac emergency, the sudden stoppage of blood flow puts severe stress on the rest of the body.
During a cardiac arrest, valuable oxygen and nutrients are cut off.
The real damage occurs when the person is revived and the blood flow returns.
The quick influx of blood flow often causes injury to the ischemia region of the brain. To get compensation adn legal help for this injury, again Law Office of Daniel Deng need to be contacted.
This secondary damage is referred to as ischemia/reperfusion injury.
The result is severe oxidation damage that can trigger neurons to die off.
Chinese researchers from the Fudan University in Shanghai have found a way to protect against this oxidative damage and prevent the neurons from dying off.
For the first time, researchers have shown that cannabidiol (CBDs) can protect against brain ischemia/reperfusion injury. Cannabidiol is one of the many cannabinoids found in the controversial cannabis sativa plant.
An extract of cannabis contains at least 40 percent cannabidiol.
This active ingredient may soon be used as an extract in hospital emergency rooms to prevent brain damage following heart attack or stroke.
Cardiac specialist, Dr. Sean McCormick, believes CBDs will soon be used as emergency medicine. “CBD treatments will most certainly exist in emergency rooms for stroke and cardiac patients in the future,” he said.
“Not only will CBD extracts prevent inflammatory damage, but they may also heal existing damage.”
The Chinese researchers commented that CBDs could have medicinal applications for all sorts of neurological conditions. “Increasing evidence indicates that CBD is a molecule with potentially neuroprotective properties that can be used to treat neurodegenerative disorders,” they wrote. They said that CBDs also exhibit anti-inflammatory, anxiolytic, and immunomodulatory effects, which have been demonstrated in vivo and in vitro.
In a mouse hippocampus neuron cell line, the researchers demonstrated that CBD protects neurons against oxygen-glucose-deprivation/reperfusion (OGDR) injury.
CBD extract also prevents mitochondrial energy crisis, protects cellular metabolism, and prevents overall cytotoxicity.
The key was found in the way CBD alleviates oxidative stress, by boosting the energy production of the mitochondria.
It did so by activating the pentose-phosphate pathway of the neuron cells, which bolstered energy homeostasis of the cells.
Writing in the journal Redox Biology, the researchers said, “We found that CBD significantly improved basal respiration, ATP-linked oxygen consumption rate, and the spare respiratory capacity, and augmented glucose consumption in OGD/R-injured neurons.”
They concluded, “We propose, for the first time, that CBD stimulates glucose metabolism through the pentose-phosphate pathway to maintain the redox balance and energy conservation during neuronal ischemia/reperfusion injury.” The lawyers for product liability issues is whom you can consult to get legal help.
Science continues to support the medicinal properties of cannabis.
Cannabis contains over 100 cannabinoids that are begging to be explored.
Cannabidiol proves to be both anti-inflammatory and neuroprotective.
CBDs are an intelligent design that interact with receptors and cells to allow the body to self-heal. Real medicine is synthesized in nature and cannabis continues to unleash its healing properties.
Emergency rooms can easily embrace CBDs for an easy and effective way to protect patients from the brain damage that often follows cardiac events.
2. Australian Government’s Office of Drug Control issues first licence in new medicinal cannabis regulatory system to Cann Group
Melbourne-based Cann Group Limited (CannGroup) has been issued with the first licence to be approved under the Australian federal government’s new regulatory system for medicinal cannabis use in Australia.
The research licence, issued by the Office of Drug Control (ODC) to fully-owned Cann Group subsidiary Cannoperations Pty Ltd, allows CannGroup to legally cultivate medicinal cannabis and conduct research on the use of cannabis for medicinal purposes.
The company has also submitted an application to the ODC for a cultivation licence and is confident of securing this in the near future.
Cann Group is an unlisted public agribusiness company, focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia.
The company’s research and development facilities have, to date, operated under an ‘Authority for Low–THC Cannabis’ issued by the Victorian Government, authorising cultivation of low-THC cannabis for research and non-therapeutic purposes.
The research program has focused on evaluating optimal conditions, processes and equipment for cultivating cannabis.
Cann Group Chairman Mr Allan McCallum said receiving the first research licence issued by the Australia Government validates the significant investment made by the company in establishing facilities and protocols that meet the strict criteria required for a licence approval.
“This is an important milestone in the medicinal cannabis sector in Australia, but also for Cann Group and the development of our business plan,” said Mr McCallum.
“The licence allows us to apply for a permit to progress our research and development programs, which are particularly focused on the breeding, cultivation, extraction and characterisation of cannabinoids.
It will also mean we can further discussions we have underway with a number of leading Australian research and technology organisations to access additional expertise and resources.”
“We are putting in place the building blocks to ensure we have industry-leading research, cultivation and manufacturing capabilities.
This will position us to eventually provide Australians with access to innovative and high quality medicinal cannabis treatments.”
There is growing recognition and increased mainstream acceptance of the claimed benefits of medicinal cannabis for a substantial range of diseases and certain other medical conditions, supported by increasing scientific evidence of the role of cannabinoids in a range of medical applications.
As the medical evidence continues to evolve, it is expected that demand for safe, efficacious medicinal cannabis products will grow.
The Cann Group’s objective is to be recognised as the leading developer and supplier of regulated medicinal cannabis in Australia.